Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report

Review Article

Abstract

Purpose

Fibrates are used to manage mixed dyslipidemia. However, these drugs have the potential risk of inducing rhabdomyolysis. This paper gives an overview of the literature on rhabdomyolysis associated with fibrate therapy.

Methods

We reported a case of rhabdomyolysis induced by fenofibrate and reviewed the published rhabdomyolysis cases associated with fibrate therapy.

Results

Seventy-six published rhabdomyolysis cases associated with fibrates were evaluated, and a nondiabetic, nonhypertensive patient who presented with rhabdomyolysis caused by fenofibrate was reported. The onset time of the reaction varied between 36 h and 6 months. Gemfibrozil was the most frequent agent associated with rhabdomyolysis, followed by bezafibrate, fenofibrate, ciprofibrate, and clofibrate. Twenty-three cases were associated with fibrate monotherapy and 54 with fibrate therapy combined with statins or other drugs potentially interacting with fibrates. Sixteen cases had chronic renal failure before fibrate therapy, and 6 had hypothyroidism. Fifty-four complicated acute renal failure. After discontinuation of the fibrates and hydration, most patients recovered.

Conclusions

Chronic renal failure may be a risk factor for rhabdomyolysis associated with fibrates. Although rhabdomyolysis usually occurred when fibrates were combined with statins, a well-known class of agents that potentially induce rhabdomyolysis, precautions against serious adverse effects should also be taken with fibrate monotherapy.

Keywords

Drug adverse reaction Rhabdomyolysis Fibrates Drug interaction 

Supplementary material

228_2009_723_MOESM1_ESM.pdf (142 kb)
Supplementary Table 1Characteristics of rhabdomyolysis cases associated with fibrates (PDF 141 kb)

References

  1. 1.
    Knopp RH (1999) Drug treatment of lipid disorders. N Engl J Med 341(7):498–511CrossRefPubMedGoogle Scholar
  2. 2.
    Davidson MH, Armani A, McKenney JM, Jacobson TA (2007) Safety considerations with fibrate therapy. Am J Cardiol 99(6A):3C–18CCrossRefPubMedGoogle Scholar
  3. 3.
    Baer AN, Wortmann RL (2007) Myotoxicity associated with lipid-lowering drugs. Curr Opin Rheumatol 19(1):67–73PubMedGoogle Scholar
  4. 4.
    Vanholder R, Sever MS, Erek E, Lameire N (2000) Rhabdomyolysis. J Am Soc Nephrol 11(8):1553–1561PubMedGoogle Scholar
  5. 5.
    Tahmaz M, Kumbasar B, Ergen K, Ure U, Karatemiz G, Kazancioglu R (2007) Acute renal failure secondary to fenofibrate monotherapy-induced rhabdomyolysis. Ren Fail 29(7):927–930CrossRefPubMedGoogle Scholar
  6. 6.
    Yildiz A, Gucuk E, Cay S (2008) A case of rhabdomyolysis and thromboembolic event secondary to fibrate monotherapy. Acta Cardiol 63(4):515–517CrossRefPubMedGoogle Scholar
  7. 7.
    Unal A, Torun E, Sipahioglu MH, Tokgoz B, Kaya MG, Oymak O et al (2008) Fenofibrate-induced acute renal failure due to massive rhabdomyolysis after coadministration of statin in two patients. Intern Med 47(11):1017–1019CrossRefPubMedGoogle Scholar
  8. 8.
    Satarasinghe RL, Ramesh R, Riyaaz AA, Gunarathne PA, de Silva AP (2007) Hypothyroidism is a predisposing factor for fenofibrate-induced rhabdomyolysis-patient report and literature review. Drug Metabol Drug Interact 22(4):279–283PubMedGoogle Scholar
  9. 9.
    Dedhia V, Munsi SC (2007) Myopathy caused by a combination rosuvastatin and fenofibrate. J Assoc Physicians India 55:152–153PubMedGoogle Scholar
  10. 10.
    Akoglu H, Yilmaz R, Kirkpantur A, Arici M, Altun B, Turgan C (2007) Combined organ failure with combination antihyperlipidemic treatment: a case of hepatic injury and acute renal failure. Ann Pharmacother 41(1):143–147PubMedGoogle Scholar
  11. 11.
    Yang KC, Fang CC, Su TC, Lee YT (2005) Treatment of fibrate-induced rhabdomyolysis with plasma exchange in ESRD. Am J Kidney Dis 45(3):e57–60CrossRefPubMedGoogle Scholar
  12. 12.
    Morimoto S, Fujioka Y, Tsutsumi C, Masai M, Okumura T, Yuba M et al (2005) Mizoribine-induced rhabdomyolysis in a rheumatoid arthritis patient receiving bezafibrate treatment. Am J Med Sci 329(4):211–213CrossRefPubMedGoogle Scholar
  13. 13.
    Kursat S, Alici T, Colak HB (2005) A case of rhabdomyolysis induced acute renal failure secondary to statin-fibrate-derivative combination and occult hypothyroidism. Clin Nephrol 64(5):391–393PubMedGoogle Scholar
  14. 14.
    Jacob SS, Jacob S, Williams C, Deeg MA (2005) Simvastatin, fenofibrate, and rhabdomyolysis. Diabetes Care 28(5):1258CrossRefPubMedGoogle Scholar
  15. 15.
    Ireland JH, Eggert CH, Arendt CJ, Williams AW (2005) Rhabdomyolysis with cardiac involvement and acute renal failure in a patient taking rosuvastatin and fenofibrate. Ann Intern Med 142(11):949–950PubMedGoogle Scholar
  16. 16.
    Fontaine C, Guiard-Schmid JB, Slama L, Essid A, Lukiana T, Rondeau E et al (2005) Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate. AIDS 19(16):1927–1928CrossRefPubMedGoogle Scholar
  17. 17.
    Layne RD, Sehbai AS, Stark LJ (2004) Rhabdomyolysis and renal failure associated with gemfibrozil monotherapy. Ann Pharmacother 38(2):232–234PubMedGoogle Scholar
  18. 18.
    Yen TH, Chang CT, Wu MS, Huang CC (2003) Acute rhabdomyolysis after gemfibrozil therapy in a pregnant patient complicated with acute pancreatitis and hypertriglyceridemia while receiving continuous veno-venous hemofiltration therapy. Ren Fail 25(1):139–143CrossRefPubMedGoogle Scholar
  19. 19.
    Barker BJ, Goodenough RR, Falko JM (2003) Fenofibrate monotherapy induced rhabdomyolysis. Diabetes Care 26(8):2482–2483CrossRefPubMedGoogle Scholar
  20. 20.
    Arenas J, Fernandez-Moreno MA, Molina JA, Fernandez V, del Hoyo P, Campos Y et al (2003) Myoglobinuria and COX deficiency in a patient taking cerivastatin and gemfibrozil. Neurology 60(1):124–126PubMedGoogle Scholar
  21. 21.
    Su M, Hoffman RS, Flomenbaum M (2002) Cerivastatin and gemfibrozil-induced cardiac rhabdomyolysis. Am J Forensic Med Pathol 23(3):305–306CrossRefPubMedGoogle Scholar
  22. 22.
    Maxa JL, Melton LB, Ogu CC, Sills MN, Limanni A (2002) Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole. Ann Pharmacother 36(5):820–823CrossRefPubMedGoogle Scholar
  23. 23.
    Marsa Carretero M, Alos Manrique C, Valles Callol JA (2002) Rhabdomyolysis associated with cerivastatin plus gemfibrozil combined regimen. Br J Gen Pract 52(476):235–236PubMedGoogle Scholar
  24. 24.
    Kind AH, Zakowski LJ, McBride PE (2002) Rhabdomyolysis from the combination of a statin and gemfibrozil: an uncommon but serious adverse reaction. WMJ 101(7):53–56PubMedGoogle Scholar
  25. 25.
    Huynh T, Cordato D, Yang F, Choy T, Johnstone K, Bagnall F et al (2002) HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions. Intern Med J 32(9–10):486–490CrossRefPubMedGoogle Scholar
  26. 26.
    Bairaktari E, Seferiadis K, Liamis G, Psihogios N, Tsolas O, Elisaf M (2002) Rhabdomyolysis-related renal tubular damage studied by proton nuclear magnetic resonance spectroscopy of urine. Clin Chem 48(7):1106–1109PubMedGoogle Scholar
  27. 27.
    Atmaca H, Sayarlioglu H, Kulah E, Demircan N, Akpolat T (2002) Rhabdomyolysis associated with gemfibrozil-colchicine therapy. Ann Pharmacother 36(11):1719–1721CrossRefPubMedGoogle Scholar
  28. 28.
    Mastroianni CM, d'Ettorre G, Forcina G, Lichtner M, Corpolongo A, Coletta S et al (2001) Rhabdomyolysis after cerivastatin-gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia. AIDS 15(6):820–821CrossRefPubMedGoogle Scholar
  29. 29.
    Lau TK, Leachman DR, Lufschanowski R (2001) Severe rhabdomyolysis associated with the cerivastin-gemfibrozil combination therapy: report of a case. Texas Heart Inst J 28(2):142–145Google Scholar
  30. 30.
    Kamaliah MD, Sanjay LD (2001) Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives. Singapore Med J 42(8):368–372PubMedGoogle Scholar
  31. 31.
    Hendriks F, Kooman JP, van der Sande FM (2001) Massive rhabdomyolysis and life threatening hyperkalaemia in a patient with the combination of cerivastatin and gemfibrozil. Nephrol Dial Transplant 16(12):2418–2419CrossRefPubMedGoogle Scholar
  32. 32.
    Federman DG, Hussain F, Walters AB (2001) Fatal rhabdomyolysis caused by lipid-lowering therapy. South Med J 94(10):1023–1026PubMedGoogle Scholar
  33. 33.
    Bruno-Joyce J, Dugas JM, MacCausland OE (2001) Cerivastatin and gemfibrozil-associated rhabdomyolysis. Ann Pharmacother 35(9):1016–1019CrossRefPubMedGoogle Scholar
  34. 34.
    Sharobeem KM, Madden BP, Millner R, Rolfe LM, Seymour CA, Parker J (2000) Acute renal failure after cardiopulmonary bypass: a possible association with drugs of the fibrate group. J Cardiovasc Pharmacol Ther 5(1):33–39CrossRefPubMedGoogle Scholar
  35. 35.
    Plotkin E, Bernheim J, Ben-Chetrit S, Mor A, Korzets Z (2000) Influenza vaccine—a possible trigger of rhabdomyolysis induced acute renal failure due to the combined use of cerivastatin and bezafibrate. Nephrol Dial Transplant 15(5):740–741CrossRefPubMedGoogle Scholar
  36. 36.
    Ozdemir O, Boran M, Gokce V, Uzun Y, Kocak B, Korkmaz S (2000) A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy-a case report. Angiology 51(8):695–697PubMedGoogle Scholar
  37. 37.
    Oldemeyer JB, Lund RJ, Koch M, Meares AJ, Dunlay R (2000) Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations. Cardiology 94(2):127–128CrossRefPubMedGoogle Scholar
  38. 38.
    Bermingham RP, Whitsitt TB, Smart ML, Nowak DP, Scalley RD (2000) Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil. Am J Health Syst Pharm 57(5):461–464PubMedGoogle Scholar
  39. 39.
    Alexandridis G, Pappas GA, Elisaf MS (2000) Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil. Am J Med 109(3):261–262CrossRefPubMedGoogle Scholar
  40. 40.
    Weissgarten J, Zaidenstein R, Fishman S, Dishi V, Michovitz-Koren M, Averbukh Z et al (1999) Rhabdomyolysis due to bezafibrate in CAPD patients. A role for dihydropyridine drugs? Perit Dial Int 19(2):180–182PubMedGoogle Scholar
  41. 41.
    Pogson GW, Kindred LH, Carper BG (1999) Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy. Am J Cardiol 83(7):1146CrossRefPubMedGoogle Scholar
  42. 42.
    Landesman KA, Stozek M, Freeman NJ (1999) Rhabdomyolysis associated with the combined use of hydroxymethylglutaryl-coenzyme A reductase inhibitors with gemfibrozil and macrolide antibiotics. Conn Med 63(8):455–457PubMedGoogle Scholar
  43. 43.
    Clouatre Y, Leblanc M, Ouimet D, Pichette V (1999) Fenofibrate-induced rhabdomyolysis in two dialysis patients with hypothyroidism. Nephrol Dial Transplant 14(4):1047–1048CrossRefPubMedGoogle Scholar
  44. 44.
    Terrovitou CT, Milionis HJ, Elisaf MS (1998) Acute rhabdomyolysis after bezafibrate re-exposure. Nephron 78(3):336–337CrossRefPubMedGoogle Scholar
  45. 45.
    Duell PB, Connor WE, Illingworth DR (1998) Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol 81(3):368–369CrossRefPubMedGoogle Scholar
  46. 46.
    Tal A, Rajeshawari M, Isley W (1997) Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. South Med J 90(5):546–547PubMedGoogle Scholar
  47. 47.
    Ramachandran S, Giles PD, Hartland A (1997) Acute renal failure due to rhabdomyolysis in presence of concurrent ciprofibrate and ibuprofen treatment. BMJ 314(7094):1593PubMedGoogle Scholar
  48. 48.
    van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ (1996) Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J Intern Med 240(6):403–404CrossRefPubMedGoogle Scholar
  49. 49.
    Panuccio V, Enia G, Parlongo S, Cutrupi S, Zoccali C (1996) Severe rhabdomyolysis induced by a retard formulation of bezafibrate in a CAPD patient. Nephron 73(4):736CrossRefPubMedGoogle Scholar
  50. 50.
    Gorriz JL, Sancho A, Lopez-Martin JM, Alcoy E, Catalan C, Pallardo LM (1996) Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy. Nephron 74(2):437–438CrossRefPubMedGoogle Scholar
  51. 51.
    Gorriz JL, Sancho A, Alcoy E, Garcia-Ramos JL, Pallardo LM (1995) Rhabdomyolysis and acute renal failure associated with bezafibrate treatment. Nephrol Dial Transplant 10(12):2371–2372PubMedGoogle Scholar
  52. 52.
    de Alava E, Sola JJ, Lozano MD, Pardo-Mindan FJ (1994) Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants. Nephron 66(2):242–243CrossRefPubMedGoogle Scholar
  53. 53.
    Bedani PL, Perini L, Gilli P (1994) Acute rhabdomyolysis and hemoglobin reduction after bezafibrate overdose in hyperlipidemic patients on hemodialysis. Nephron 68(4):512–513CrossRefPubMedGoogle Scholar
  54. 54.
    Kanterewicz E, Sanmarti R, Riba J, Trias I, Autonell J, Brugues J (1992) Bezafibrate induced rhabdomyolysis. Ann Rheum Dis 51(4):536–538CrossRefPubMedGoogle Scholar
  55. 55.
    Pierce LR, Wysowski DK, Gross TP (1990) Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 264(1):71–75CrossRefPubMedGoogle Scholar
  56. 56.
    Goldman JA, Fishman AB, Lee JE, Johnson RJ (1989) The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis. Arthritis Rheum 32(3):358–359CrossRefPubMedGoogle Scholar
  57. 57.
    Haubenstock A, Schrocksnadel W, Bauer K, Schmidt P, Gabl F (1984) Predominance of lactate dehydrogenase isoenzyme 1 in a patient with bezafibrate-induced rhabdomyolysis. Clin Chem 30(9):1587–1588PubMedGoogle Scholar
  58. 58.
    Smals AG, Beex LV, Kloppenborg PW (1977) Clofibrate-induced muscle damage with myoglobinuria and cardiomyopathy. N Engl J Med 296(16):942PubMedGoogle Scholar
  59. 59.
    Waring WS, Wrate J, Bateman DN (2006) Olanzapine overdose is associated with acute muscle toxicity. Hum Exp Toxicol 25(12):735–740CrossRefPubMedGoogle Scholar
  60. 60.
    Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L et al (2004) Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292(21):2585–2590CrossRefPubMedGoogle Scholar
  61. 61.
    Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E et al (2003) Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 163(5):553–564CrossRefPubMedGoogle Scholar
  62. 62.
    Jacobson TA, Zimmerman FH (2006) Fibrates in combination with statins in the management of dyslipidemia. J Clin Hypertens (Greenwich) 8(1):35–41 quiz 42–33CrossRefGoogle Scholar
  63. 63.
    Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365(9468):1415–1428CrossRefPubMedGoogle Scholar
  64. 64.
    Staffa JA, Chang J, Green L (2002) Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346(7):539–540CrossRefPubMedGoogle Scholar
  65. 65.
    Franssen R, Vergeer M, Stroes ES, Kastelein JJ (2009) Combination statin-fibrate therapy: safety aspects. Diabetes Obes Metab 11(2):89–94CrossRefPubMedGoogle Scholar
  66. 66.
    Maiguma T, Fujisaki K, Itoh Y, Makino K, Teshima D, Takahashi-Yanaga F et al (2003) Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells. Naunyn Schmiedebergs Arch Pharmacol 367(3):289–296CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  1. 1.Kidney Disease Center, First Affiliated Hospital, College of MedicineZhejiang UniversityHanghzouPeople’s Republic of China

Personalised recommendations